Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2022-11-16 Earnings Release
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 95% confidence The document is an official press release from Mauna Kea Technologies announcing their financial results for the first half of 2022. It contains key financial highlights, income statement tables, and management commentary. While it references that the full semi-annual financial report will be available later, the document itself provides substantive financial data and analysis, qualifying it as an Earnings Release (ER) rather than a mere publication announcement (RPA). H1 2022
2022-11-16 French
Inside Information / Other news releases
M&A Activity Classification · 99% confidence The document is a press release dated November 7, 2022, announcing a significant business development: the incorporation of a Joint Venture (Tasly Mauna Kea Medical Engineering Technology Co. Ltd.) between Mauna Kea Technologies and Tasly Pharmaceutical Group to expand Cellvizio reach in China and launch neurosurgical applications worldwide. This type of announcement, detailing strategic partnerships, joint venture formation, and capital structure changes related to that venture (RMB 250 million registered capital), fits best under 'Capital/Financing Update' (CAP) as it directly relates to a major capital commitment and structural change for commercial expansion. It is not a standard regulatory filing like 10-K, an earnings release (ER), or a proxy statement. While it involves corporate activity, 'CAP' is the most specific fit for announcing the formal establishment and capitalization of a new entity resulting from a strategic partnership.
2022-11-07 English
Informations privilégiées / Autres communiqués
M&A Activity Classification · 95% confidence The document is a press release dated November 7, 2022, announcing the creation and legal constitution of a Joint Venture between Mauna Kea Technologies and Tasly Pharmaceutical Group. This announcement details a strategic partnership, capital structure of the JV, and future commercial plans. This type of announcement, which concerns strategic business development and corporate structuring (though not explicitly a financing round or M&A takeover bid), is best classified as a general corporate announcement. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific shareholder vote result (DVA), and it is not a presentation (IP) or a transcript (CT), the most appropriate category is the general regulatory announcement fallback, RNS, as it is a significant corporate update released to the public/market. However, given the focus on a major strategic partnership and the formation of a new entity, it strongly relates to corporate activity that might be covered under broader corporate updates. Reviewing the definitions, 'M&A Activity (TAR)' is for merger proposals or takeover bids, which this JV formation is related to but not strictly defined as. 'Capital/Financing Update (CAP)' is for fundraising/capital structure changes, which is partially true for the JV capital, but the core is the partnership. Since this is a press release announcing a major business development (JV formation), and it doesn't fit perfectly into the highly specific financial reporting categories, RNS (Regulatory Filings - general regulatory announcements) is the most suitable fallback, although it shares characteristics with M&A/Partnership announcements not explicitly listed. Given the context of a press release announcing a significant corporate event, RNS is the standard catch-all for non-standard, material announcements.
2022-11-07 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated October 31, 2022, announcing the success of a clinical trial and its publication in the journal *Gastroenterology*. It details clinical results, provides background information on IBD, and includes standard forward-looking statements and investor relations contacts. This format—an announcement of a significant event (clinical trial success/publication) issued via press release—does not fit the definitions for formal regulatory filings like 10-K, IR, or ER. It is not a management presentation (IP), a transcript (CT), or a specific financial report (AR, IR). Since it is a general announcement of a significant corporate/scientific development that doesn't fit the highly specific categories (like DIRS, DIV, CAP, etc.), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings).
2022-10-31 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated October 31, 2022, announcing the success of a clinical study regarding Inflammatory Bowel Disease (IBD) and its publication in the journal *Gastroenterology*. It details clinical results, provides context about the disease and the company's technology (Cellvizio®), and includes investor relations contact information and a forward-looking statements disclaimer. This format—an announcement of results and key findings, often released before or alongside a formal filing—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K or IR), nor a transcript (CT), nor a specific regulatory filing like DIRS or DIV, and it focuses on announcing key operational/clinical results, the most appropriate classification is Earnings Release (ER), as these often include significant operational milestones alongside financial highlights, or Regulatory Filing (RNS) as a general announcement. Given the focus on announcing a major clinical study result and its publication, it functions as a significant corporate update. However, since it is not explicitly labeled as an 'Earnings Release' but rather an 'announcement' of a study success and publication, and it doesn't contain typical quarterly financial tables, it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but it reads like a press release. Given the options, and recognizing that many non-standard, material announcements fall under RNS, I will select RNS as the most general fit for a material press release that isn't a core financial report or a specific event announcement like DIV or DIRS. If the document were purely about financial performance, ER would be better. Since it's about a clinical/scientific milestone announcement, RNS is a strong candidate, or potentially LTR if the focus was purely on legal/regulatory outcomes, but this is a positive scientific announcement. I will lean towards RNS as the best fit for a material, non-standard press release.
2022-10-31 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 100% confidence The document is titled "Mauna Kea Technologies annonce ses ventes des neuf premiers mois 2022" (Mauna Kea Technologies announces its sales for the first nine months of 2022). It presents key financial figures (revenue, sales breakdown by segment and geography) for the third quarter (T3) and the first nine months (9M) of 2022, comparing them to the previous year. This structure—providing detailed, period-specific financial results shortly after the period ends—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it covers nine months (a significant interim period) and provides detailed tables and management commentary on performance, it aligns best with the definition of an Interim / Quarterly Report (IR), which is a comprehensive report for a period shorter than a year. It is more detailed than a typical Earnings Release (ER) which usually provides only key highlights. 9M 2022
2022-10-27 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.